Intrexon | XON - Ebitda


Intrexon reported $-24.7M in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 3.86B 1.28B Mar/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Incyte USD 778.57M 410.6M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
MannKind USD 2.93M 5.98M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Roche Holding CHF 13.43B 744M Jun/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
Veracyte USD 43.96M 1.16M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026